Stocktoria
IOVANCE BIOTHERAPEUTICS, INC. IOVA
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $263.5M at a -148.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.5 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.333 |
| Retained earnings / assets | -3.039 |
| EBIT / assets | -0.442 |
| Equity / liabilities | 3.255 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | 2/9 | -7.27 | — | +60.6% |
| VCEL | Vericel Corp | 7/9 | 3.1 | 118.9 | +16.5% |
| VXRT | Vaxart, Inc. | 5/9 | -4.73 | 8.3 | +726.7% |
| ADAPY | Adaptimmune Therapeutics PLC | 3/9 | -13.03 | — | +195.3% |
| RGNX | REGENXBIO Inc. | 3/9 | -7.82 | — | +104.5% |
| TWST | Twist Bioscience Corp | 3/9 | -2.72 | — | +20.3% |
| KRYS | Krystal Biotech, Inc. | 5/9 | 16.61 | 53.6 | +33.9% |
About IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
FAQ
Is IOVA financially healthy?
IOVANCE BIOTHERAPEUTICS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IOVA pay a dividend?
No, IOVANCE BIOTHERAPEUTICS, INC. does not currently pay a dividend.
How profitable is IOVA?
In FY2025, IOVANCE BIOTHERAPEUTICS, INC. had a net margin of -148.4% and a return on equity of -56.0%.
What is the analyst price target for IOVA?
The average Wall-Street price target for IOVANCE BIOTHERAPEUTICS, INC. is $8.80, about 30.6% above the recent price, from 10 analysts (consensus: buy).
Is IOVA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IOVANCE BIOTHERAPEUTICS, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.